Research Analysts’ Recent Ratings Changes for Dyne Therapeutics (DYN)

A number of research firms have changed their ratings and price targets for Dyne Therapeutics (NASDAQ: DYN):

• 9/4/2024 – Dyne Therapeutics had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $55.00 price target on the stock.
• 9/3/2024 – Dyne Therapeutics had its “outperform” rating reaffirmed by analysts at Oppenheimer Holdings Inc.. They now have a $55.00 price target on the stock.
• 8/30/2024 – Dyne Therapeutics was upgraded by analysts at StockNews.com from a “sell” rating to a “hold” rating.
• 8/24/2024 – Dyne Therapeutics was downgraded by analysts at StockNews.com from a “hold” rating to a “sell” rating.
• 8/17/2024 – Dyne Therapeutics was upgraded by analysts at StockNews.com from a “sell” rating to a “hold” rating.
• 8/16/2024 – Dyne Therapeutics had its price target raised by analysts at Stifel Nicolaus from $41.00 to $66.00. They now have a “buy” rating on the stock.
• 8/15/2024 – Dyne Therapeutics had its price target raised by analysts at Guggenheim from $45.00 to $50.00. They now have a “buy” rating on the stock.
• 8/14/2024 – Dyne Therapeutics had its price target raised by analysts at Morgan Stanley from $48.00 to $52.00. They now have an “overweight” rating on the stock.
• 8/13/2024 – Dyne Therapeutics had its price target raised by analysts at Piper Sandler from $43.00 to $53.00. They now have an “overweight” rating on the stock.
• 8/13/2024 – Dyne Therapeutics had its price target raised by analysts at HC Wainwright from $48.00 to $55.00. They now have a “buy” rating on the stock.

Dyne Therapeutics Stock Down 1.7 %

NASDAQ DYN opened at $32.47 on Tuesday. Dyne Therapeutics, Inc. has a 52-week low of $6.40 and a 52-week high of $47.45. The firm has a 50-day moving average price of $41.52 and a 200 day moving average price of $33.12. The stock has a market capitalization of $3.26 billion, a P/E ratio of -8.18 and a beta of 1.07.

Dyne Therapeutics (NASDAQ:DYN) last posted its quarterly earnings results on Monday, August 12th. The company reported ($0.70) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.72) by $0.02. On average, equities research analysts expect that Dyne Therapeutics, Inc. will post -2.96 earnings per share for the current fiscal year.

Insider Transactions at Dyne Therapeutics

In other news, CEO John Cox purchased 32,000 shares of the business’s stock in a transaction dated Wednesday, September 4th. The stock was acquired at an average price of $33.04 per share, with a total value of $1,057,280.00. Following the purchase, the chief executive officer now directly owns 8,000 shares of the company’s stock, valued at approximately $264,320. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. In other Dyne Therapeutics news, COO Susanna Gatti High sold 40,000 shares of the firm’s stock in a transaction on Wednesday, June 12th. The stock was sold at an average price of $33.36, for a total transaction of $1,334,400.00. Following the completion of the transaction, the chief operating officer now owns 148,792 shares of the company’s stock, valued at $4,963,701.12. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO John Cox purchased 32,000 shares of the business’s stock in a transaction dated Wednesday, September 4th. The stock was bought at an average cost of $33.04 per share, with a total value of $1,057,280.00. Following the completion of the acquisition, the chief executive officer now owns 8,000 shares of the company’s stock, valued at $264,320. The disclosure for this purchase can be found here. Insiders have sold 79,950 shares of company stock valued at $2,736,302 in the last quarter. 20.77% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the business. AQR Capital Management LLC raised its stake in Dyne Therapeutics by 4.3% during the second quarter. AQR Capital Management LLC now owns 8,495 shares of the company’s stock worth $300,000 after purchasing an additional 352 shares during the period. Nisa Investment Advisors LLC raised its position in shares of Dyne Therapeutics by 904.1% in the 2nd quarter. Nisa Investment Advisors LLC now owns 743 shares of the company’s stock worth $26,000 after buying an additional 669 shares during the period. Amalgamated Bank boosted its holdings in Dyne Therapeutics by 39.9% in the second quarter. Amalgamated Bank now owns 2,792 shares of the company’s stock valued at $99,000 after acquiring an additional 796 shares during the last quarter. Principal Financial Group Inc. grew its position in Dyne Therapeutics by 5.9% during the first quarter. Principal Financial Group Inc. now owns 15,403 shares of the company’s stock valued at $437,000 after acquiring an additional 857 shares during the period. Finally, Wetzel Investment Advisors Inc. acquired a new stake in Dyne Therapeutics during the first quarter worth about $28,000. Hedge funds and other institutional investors own 96.68% of the company’s stock.

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.